₹ 14868 / 14 Shares Shares
Minimum Investment
₹1008-1062 per equity share
08 Dec 2025
10 Dec 2025
14
₹ 14868
₹1008-1062
15 Dec 2025
61,71,101 shares(aggregating up to ₹655.37 crore)
₹10 Per Equity Share
14 Shares
14 Shares
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women's healthcare, cardiology, pain management, urology, and other therapeutic areas. The diversified portfolio of the company as of December 2024 comprises 67 brands across therapeutic areas such as women's healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals, including vitamins/minerals/nutrition, gastrointestinal, and respiratory.The company has a pan-India marketing and distribution network with 2,598 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, thus consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas. Presently, the company owns two manufacturing facilities located in the states of Gujarat. As of December 31, 2024, the company had 88 R&D employees.
2004
Dr. Kirtikumar Laxmidas Mehta
Corona Remedies Limited IPO
| Apply as | Price Range | Apply Upto |
|---|---|---|
| Retail (min) | ₹1008-1062 | ₹14,868 |
| Retail(max) | ₹1008-1062 | ₹1,93,284 |
| SHNI(min) | ₹1008-1062 | ₹2,08,152 |
| SHNI(max) | ₹1008-1062 | ₹9,96,156 |
| BHNI(min) | ₹1008-1062 | ₹10,11,024 |
For Corona Remedies Limited IPO, eligible investors can apply as Regular.
Yes, joint investments are allowed with a resident Indian, provided KYC and bank account norms are met.
A nominal processing fee may apply depending on the lender. KSquare clearly discloses all charges upfront.
Open-ended NFOs usually have no lock-in, while close-ended ones might restrict withdrawals for a specific term.
You can withdraw your invested amount anytime. However, early exits might impact your long-term growth potential.
KSquare provides tax guidance specific to NRIs, helping you plan and stay compliant with Indian tax laws.
Yes, most lenders require mutual fund units in demat form. KSquare can help convert physical units if needed.
No, SIPs don’t guarantee returns but reduce risk over time and provide the potential for solid, market-linked growth.
Units are credited within a few days after the NFO closes and the scheme is processed by the fund house.